Alesi Surgical Ltd

Alesi Surgical announced in 2023 that it had attained FDA clearance for its groundbreaking Ultravision2 smoke management solution. The breakthrough new Ultravision system includes the world’s first surgical tool integrating electrosurgery and class-leading surgical smoke control in a single laparoscopic device. Alesi Surgical was founded to develop and commercialise products that improve the safety, efficacy, and outcomes of surgical procedures. The company is a spin-out of the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre in the UK. Alesi Surgical has a unique level of access to experienced surgeons, surgical trainers, and trainees, which allows it to identify issues in procedures and design devices to address these issues. The company is active in the research and development of novel surgical technologies. It has a ‘needs-driven’ pipeline and product development is informed by robust testing by surgical trainers who advise on the utility, usability, and integration of products into surgical practice. Ultravision is designed to deliver rapid and continuous resolution of surgical smoke. It is a small, stand-alone, portable unit fully compatible with current laparoscopic equipment and electrosurgical instruments. Alesi Surgical welcomes approaches from research-based companies or inventors who are interested in exploring potential synergies.